Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
Already Have An Account? Log in Now
Bacterial Keratitis: Drop Instillation Regimes and Treatment Failure
abstract
This abstract is available on the publisher's site.
Access this abstract now Full Text Available for ClinicalKey SubscribersBacterial keratitis (BK) presentations are often treated using the commercially available second-generation fluoroquinolones ciprofloxacin 0.3% and ofloxacin 0.3% as monotherapy. The guidelines available for instillation regimes are often not supported by data from clinical studies. This review examines the peer-reviewed clinical studies and compared treatment failure rates for ciprofloxacin 0.3% and ofloxacin 0.3% for BK in relation to Day-1 drop-regimes. From the statistical analysis, this review derived evidence-based clinically applicable minimum drop-regimes for the treatment of BK on Day-1. Lower numbers of drops of ciprofloxacin on Day-1 were significantly associated with increased treatment failure rates (p < 0.002). The derived minimum number of drops on Day for ciprofloxacin on Day-1 was 47 drops, and for ofloxacin 24 drops. The mean number of drops used in the clinical studies was significantly lower than the manufacturers' recommended Day-1 regimes for both ciprofloxacin (p = 0.0006) and ofloxacin (p = 0.048). From Day-3 to -6 of treatment the drop rates for ciprofloxacin relative to recommended rates were higher, and for ofloxacin lower (p = 0.014). The findings of this review were then compared with a representative sample of published guidelines and case studies to determine the validity of applying those drop-regimes in clinical practice. Although the manufacturers' suggested minimum drop-regimes on Day-1 were significantly different (120 drops ciprofloxacin, 34 drops ofloxacin, p < 0.0001), many of the published guidelines suggested the same drop-regime for both fluoroquinolones. The suggested drop numbers on Day-1 for ciprofloxacin in these guidelines and case studies were significantly less than those used in the clinical studies (p = 0.043). Increased treatment failure rates for ciprofloxacin are associated with lower drop numbers on Day-1. The Day-1 dosing rates for ciprofloxacin and ofloxacin should be considered separately, and the regimes suggested in published guidelines and case studies may need be re-considered in light of the findings of this review.
Additional Info
Disclosure statements are available on the authors' profiles:
The clinical treatment of bacterial keratitis: A review of drop instillation regimes
Cont Lens Anterior Eye 2022 Jun 17;[EPub Ahead of Print], JG Pearce, RW Essex, T MaddessFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The authors investigated the clinical efficacy of monotherapy of second-generation fluoroquinolones (ciprofloxacin 0.3% and ofloxacin 0.3%) in the treatment of bacterial keratitis (BK) in existing peer-reviewed clinical studies. These specific antibiotics were chosen due to their commercial availability in the authors’ home country of Australia and the finding that 96% of corneal scrapings in Australia were susceptible to second-generation fluoroquinolones. The authors found that the failure rate of ciprofloxacin was associated with a lower number of drops instilled on day 1 of treatment. Their regression analysis demonstrated a failure rate of 7% with 47 drops instilled on day 1. There was no association between the failure rate of ofloxacin and the number of drops instilled on day 1, but the analysis did suggest using a high number of drops on day 1. Interestingly, there was a large difference in the manufacturers’ guidelines of drop instillation at day 1 between ciprofloxacin and ofloxacin (120 drops vs 34 drops). Ofloxacin had a failure rate of 7% with 24 drops instilled during day 1 of treatment. In addition, there was no difference in failure rates with either ciprofloxacin or ofloxacin in the presence of systemic disease, contact lens use, and diameter of cornea infiltrates. The authors demonstrated that the specific fluoroquinolone matters with regard to the minimum number of drops needed on day 1 of treatment. A high instillation rate of second-generation fluoroquinolones of at least 1 drop per hour for 24 hours during the first day of treatment had a lower failure rate. The results of this study could be applied to other countries with similar availability of fluoroquinolones. It may not be as applicable in the USA, as multiple fourth-generation fluoroquinolones are commercially available there.